Bionano Genomics Equity Warrants Exp 21 Sep 2023 *W EXP 09/21/2023
Change company Symbol lookup
Select an option...
BNGOW Bionano Genomics Equity Warrants Exp 21 Sep 2023 *W EXP 09/21/2023
CVR Chicago Rivet & Machine Co
T AT&T Inc
HOMB Home BancShares Inc
ALG Alamo Group Inc
MGNX MacroGenics Inc
PSEC Prospect Capital Corp
SPEC Spectralcast Inc
RC Ready Capital Corp

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

Closing Price
Day's Change
-0.0312 (-10.06%)
B/A Size
Day's High
Day's Low

10-day average volume:

Rivian has been a 'train wreck,' but could be turning a corner

2:28 pm ET May 12, 2022 (MarketWatch)

By Claudia Assis

Rivian stock extends rally after mixed quarterly earnings

Rivian Automotive Inc.'s stock extended its rally Thursday as investors cheered the EV maker's intact goals for the year, but Wall Street expects the road to volume production to remain a bumpy one for Rivian.

Rivian (RIVN) stock rose more than 20% Thursday, after a similar rally late Wednesday following the company's first-quarter results. Rivian posted a wider loss than analysts expected and revenue also disappointed, but the EV maker kept its production guidance at 25,000 EVs this year.

Besides the good news regarding the production outlook, investors likely also cheered management's assurance that the $17 billion in cash on hand will be enough to launch the platform for a cheaper EV out of the future Rivian plant in Georgia, Alex Potter with Piper Sandler said in a note Thursday.

See also: Lordstown stock soars more than 30% as Foxconn factory sale goes through

"Assuming the company sticks to this plan, no capital raises should be required between now and 2025," Potter said. Management's comments "will help reassure jittery investors who are shunning unprofitable, capital intensive businesses like Rivian" amid the market downturn, the analyst said.

"We still think Rivian has the right strategy, brand, and products to be a long-term winner; macro headwinds notwithstanding," Potter said, keeping Rivian stock among Piper Sandler's top picks with a buy rating.

Don't miss: Fisker, Foxconn confirm build of compact EV in Lordstown plant

Thursday's gains took some of the sting of steep recent losses for Rivian shares amid news that some of the company's major backers, including Ford Motor Co. (F), promptly sold shares as soon as the initial public offering lockup period expired.

Rivian stock is looking at a 14% decline for the week. The shares are down 76% this year, compared with losses of around 18% for the S&P 500 index.

Investors have become "increasingly concerned" about Rivian's need for additional capital on top of the pressure from the end of the IPO lockup, Joseph Spak with RBC Capital said.

The cash on hand seems to give Rivian a "clear path" to launch the platform for its cheaper EV platform, Spak said. The figure was much better than expected, likely because Rivian became more prudent with its product roadmap and operational costs, the analyst said.

Dan Ives at Wedbush put it more bluntly: "Rivian has been a train wreck since its IPO and an overall black eye for the EV industry," but it could be turning a corner.

"To say the Rivian story has been disappointing to us (and the Street) so far would be an understatement," Ives said.

From a core engineering and design point of view and its commercial relationship with Inc. (AMZN), Rivian "has potential to be a major EV stalwart over the next decade," Ives said.

"However, for that to happen they need to start delivering models to customers and stop the excuses."

-Claudia Assis


(END) Dow Jones Newswires

May 12, 2022 14:28 ET (18:28 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.